|
Male Sex, No. (%)
|
83(44.1)
|
103 (49.8)
|
0.382
|
11.3
|
|
Age, mean (SD), y
|
68.2 (8.8)
|
66.1 (9)
|
0.046
|
24.1
|
|
BMI (kg/m2), mean (SD)
|
29.4 (4.9)
|
28.5 (4.7)
|
0.288
|
19.1
|
|
Blood pressure (mmHg), mean (SD)
| | | | |
|
Systolic
|
134.7 (12.6)
|
133.8 (14.3)
|
0.791
|
6.1
|
|
Diastolic
|
78.3 (7.7)
|
80.8 (7.4)
|
0.002
|
− 32.8
|
|
Systolic BP target, No. (%)
|
95 (50.5)
|
112 (54.1)
|
0.142
|
− 17.0
|
|
Diastolic BP target, No. (%)
|
150 (79.8)
|
136 (65.7)
|
0.274
|
19.2
|
|
Blood Pressure Target, No. (%)
|
90 (47.9)
|
105 (55.3)
|
0.193
|
− 14.8
|
|
Creatinine (mg/dL), mean (SD)
|
1.16 (0.5)
|
1.17 (0.5)
|
0.564
|
− 1.4
|
|
eGFR EPI-CKD (mL/min/m2), mean (SD)
|
62.7 (21.2)
|
65.4 (23)
|
0.350
|
− 12.1
|
|
eGFR EPI-CKD stage, No. (%)
| | | | |
|
1
|
20 (10.6)
|
45 (21.7)
|
0.600
|
− 31.1
|
|
2
|
80 (42.6)
|
77 (37.2)
| | |
|
3
|
76 (40.4)
|
71 (34.3)
| | |
|
4
|
10 (5.3)
|
11 (5.3)
| | |
|
5
|
2 (1.1)
|
3 (1.5)
| | |
|
Albuminuria (mg/day), median [IQR]
|
57.3 [35—158.1]
|
120.5 [75.8 – 223.8]
|
0.115
|
− 25.2
|
|
Haemoglobin (mg/dL), mean (SD)
|
13.4 (1.3)
|
12.9 (1.5)
|
0.377
|
36.8
|
|
Glycemia (mg/dL), mean (SD)
|
152.7 (49)
|
155.9 (43.1)
|
0.924
|
− 6.9
|
|
HbA1c (%), mean (SD)
|
7.3 (1.1)
|
7.5 (1.1)
|
0.345
|
− 18.2
|
|
HbA1c Target, No. (%)
|
100(53.2)
|
66 (31.9)
|
0.001
|
43.1
|
|
Diabetes duration, median [IQR], y
|
9 (6–15)
|
9 (7–16)
|
0.801
|
− 11.4
|
|
Cholesterol (mg/dL), mean (SD)
| | | | |
|
Total
|
185.8 (34.1)
|
187.6 (33.2)
|
0.688
|
− 5.5
|
|
LDL
|
111.5 (30.8)
|
107.5 (27)
|
0.703
|
13.7
|
|
Total Cholesterol Target, No. (%)
|
67 (35.6)
|
64 (30.9)
|
0.475
|
5.6
|
|
HDL Cholesterol Target, No. (%)
|
99 (52.7)
|
75 (36.2)
|
0.237
|
14.5
|
|
LDL Cholesterol Target, No. (%)
|
73 (38.8)
|
69 (33.3)
|
0.911
|
6.2
|
|
Triglycerides (mg/dL), median (IQR)
|
111 (88 – 153)
|
148 (115 – 190)
|
0.063
|
− 42.7
|
|
Therapy
| | | | |
|
Anti-hypertensive Therapy, No. (%)
| | |
0.791
|
− 24.8
|
|
1
|
105 (55.9)
|
94 (45.4)
| | |
|
2
|
20 (10.6)
|
31 (15)
| | |
|
3
|
32 (17)
|
44 (21.3)
| | |
|
4
|
18 (9.6)
|
27 (13)
| | |
|
5
|
13 (6.9)
|
11 (5.3)
| | |
|
ACEi/ARBs, No. (%)
| | | | |
|
ACEi
|
119 (63.2)
|
125 (60.2)
|
0.748
|
− 25.6
|
|
ARBs
|
66 (35.4)
|
77 (37.4)
| | |
|
ACE + ARBs
|
3 (1.4)
|
5 (2.4)
| | |
|
Diuretics, No. (%)
|
83 (44.1)
|
113 (54.6)
|
0.840
|
− 21.0
|
|
Calcium Channel Blockers, No. (%)
|
63 (33.5)
|
82 (39.6)
|
0.792
|
− 12.7
|
|
Beta-blockers, No. (%)
|
31 (16.5)
|
38 (18.4)
|
0.655
|
− 4.9
|
|
Alpha-blockers, No. (%)
|
13 (6.9)
|
11 (5.3)
|
0.395
|
6.7
|
|
Diabetes Therapy, No. (%)
| | |
0.361
|
− 27.7
|
|
Diet
|
16 (8.5)
|
5 (2.4)
| | |
|
Insulin
|
50 (26.6)
|
60 (29)
| | |
|
Oral anti-hyperglycemics*
|
97 (51.6)
|
108 (52.2)
| | |
|
Combined Therapy
|
25 (13.3)
|
33 (15.9)
| | |
|
Missing
|
0 (–)
|
1 (0.5)
| | |
|
Statins, No. (%)
| | |
0.569
|
− 10.8
|
|
Yes
|
72 (38.3)
|
89 (43)
| | |
|
Missing
|
0 (–)
|
3 (1.4)
| | |
|
Antiplatelets, No. (%)
| | |
0.057
|
− 58.8
|
|
Yes
|
71 (37.8)
|
126 (60.9)
| | |
|
Missing
|
0 (–)
|
16 (7.7)
| | |
